Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?
In licensing Maze’s oral contender, the group has made another bet against gene therapies.
Developers like Vertex, Regeneron and Novo Nordisk have significantly upped R&D spending in recent years, and become important acquirers.
R&D spending by the world’s largest drug makers flatlined in 2022, with Roche footing the biggest bill and Astrazeneca the fastest accelerator.